The Polymyositis drugs in development market research report provides comprehensive information on the therapeutics under development for Polymyositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Polymyositis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Polymyositis and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Polymyositis by seven companies/universities/institutes. The top development phase for Polymyositis is phase ii with five drugs in that stage. The Polymyositis pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Polymyositis pipeline products market are: Merck, Pfizer and AstraZeneca.
The key targets in the Polymyositis pipeline products market include Glucagon Like Peptide 1 Receptor (GLP1R), Interferon Alpha/Beta Receptor 1 (Cytokine Receptor Class II Member 1 or Cytokine Receptor Family 2 Member 1 or Type I Interferon Receptor 1 or IFNAR1), and Interferon Beta (Fibroblast Interferon or IFNB or IFNB1).
The key mechanisms of action in the Polymyositis pipeline product include Glucagon Like Peptide 1 Receptor (GLP1R) Agonist with one drug in Phase II. The Polymyositis pipeline products include three routes of administration with the top ROA being Intravenous and five key molecule types in the Polymyositis pipeline products market including Monoclonal Antibody, and Small Molecule.
Polymyositis overview
Polymyositis are a group of rare diseases called the inflammatory myopathies that involve chronic (long-standing) muscle inflammation and weakness, and in some cases, pain. Myopathy is used to describe a number of conditions affecting the muscles. All myopathies can cause muscle weakness. Both children and adults can be affected.
For a complete picture of Polymyositis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
